KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Goodwill (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Goodwill for 15 consecutive years, with $21.7 billion as the latest value for Q1 2025.

  • On a quarterly basis, Goodwill changed N/A to $21.7 billion in Q1 2025 year-over-year; TTM through Mar 2025 was $21.7 billion, a N/A change, with the full-year FY2023 number at $21.2 billion, changed 0.09% from a year prior.
  • Goodwill was $21.7 billion for Q1 2025 at Bristol Myers Squibb, up from $21.2 billion in the prior quarter.
  • In the past five years, Goodwill ranged from a high of $21.7 billion in Q1 2025 to a low of $20.5 billion in Q4 2021.
  • A 4-year average of $21.1 billion and a median of $21.1 billion in 2022 define the central range for Goodwill.
  • Peak YoY movement for Goodwill: decreased 0.22% in 2021, then rose 3.16% in 2022.
  • Bristol Myers Squibb's Goodwill stood at $20.5 billion in 2021, then increased by 3.16% to $21.1 billion in 2022, then rose by 0.09% to $21.2 billion in 2023, then grew by 2.68% to $21.7 billion in 2025.
  • Per Business Quant, the three most recent readings for BMY's Goodwill are $21.7 billion (Q1 2025), $21.2 billion (Q4 2023), and $21.1 billion (Q3 2023).